Saito, Yoshimasa

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬物治療学講座 (Shiba-Kyoritsu)

Position

Professor
Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Tumor diagnostics and therapeutics

Page Top ▲
 

Books 【 Display / hide 】

  • 遺伝子診断と個別化医療.「ゲノム創薬科学」

    Saito Yoshimasa, 裳華房, 2017.10

    Scope: pp269-287

  • エピジェネティクスとアンチエイジング医学.「アンチエイジング医学の基礎と臨床」第3版.

    齋藤 義正, メジカルビュー社, 東京, 2015.09

    Scope: pp42-44

  • Advanced Glycation End-products (AGEs)阻害薬がOLEFTラットの肝および脂肪組織に及ぼす影響. 「酸化ストレスと肝疾患 8巻」.

    木村真規、南雲まい、飯田陽子、山田華名、齋藤義正、齋藤英胤., 株式会社嵯峨野, 東京, 2012.09

    Scope: pp67-72

  • 加齢と消化器系の変化.「高齢者用食品の開発と展望」.

    齋藤義正、齋藤英胤., シーエムシー出版, 東京, 2012.07

    Scope: pp7-12

Page Top ▲

Papers 【 Display / hide 】

  • Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Diego F. Calvisi , Luke Boulter , Javier Vaquero , Anna Saborowski , Luca Fabris , Pedro M. Rodrigues , Cédric Coulouarn , Rui E. Castro , Oreste Segatto , Chiara Raggi , Luc J. W. van der Laan , Guido Carpino , Benjamin Goepper , Stephanie Roessler , Timothy J. Kendall , Matthias Ever , Ester Gonzalez-Sanchez , Juan W. Valle , Arndt Vogel , John Bridgewater , Mitesh J. Borad , Gregory J. Gores , Lewis R. Roberts , Jose J. G. Marin , Jesper B. Andersen , Domenico Alvaro , Alejandro Forner , Jesus M. Banales , Vincenzo Cardinale , Rocio I. R. Macias , Silve Vicen , Xin Chen , Chiara Braconi , Monique M , A. Verstegen , Laura Fouassier , Lewis Roberts , Alexander Scheiter , Florin M. Selaru , Katja Ever , Kirsten Utpatel , Laura Broutier , Massimiliano Cadamuro , Meritxell Huch , Robert Goldin , Sergio A. Gradilone , Yoshimasa Saito

    Nature Reviews Gastroenterology & Hepatology 20 ( 7 ) 462 - 480 2023.02

    Research paper (scientific journal), Joint Work, Accepted

  • Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen

    Inokuchi K., Mori H., Matsuzaki J., Hirata K., Harada Y., Saito Y., Suzuki H., Kanai T., Masaoka T.

    Helicobacter (Helicobacter)  27 ( 4 )  2022.08

    ISSN  10834389

    　View Summary

    Background: Rifabutin-based regimens are used as rescue therapy for refractory Helicobacter pylori infection; however, the duration for which treatment is required and side effects are concerning. This study assessed the efficacy and safety of 7-day rifabutin, amoxicillin, and vonoprazan triple therapy as third- or later-line treatment for H. pylori infection. Materials and Methods: Patients who did not respond to second-line therapy were enrolled. After H. pylori infection was confirmed with the culture method, the patients received rifabutin-containing triple therapy (20 mg vonoprazan b.i.d., 500 mg amoxicillin q.i.d., and 150 mg rifabutin q.d.) for 7 days. Twelve weeks after the eradication therapy, successful eradication was confirmed using a 13C urea breath test or the H. pylori stool antigen test. The results obtained from our previous study that reported a 10-day or 14-day esomeprazole based rifabutin-containing triple therapy as a third- or fourth-line rescue therapy treated patients were used as historical control. We determined the minimum inhibitory concentrations of amoxicillin and rifabutin. We also evaluated whether the patients were positive for the mutation of the rpoB gene. Results: Intention-to-treat and per-protocol analyses showed that our regimen resulted in a high eradication rate (91.2%, 95% CI: 84%–99% and 92.7%, 95% CI: 86%–100%, respectively). Adverse events occurred in 31.6% of the patients, and two patients discontinued the therapy. Conclusions: This is the first study to evaluate the efficacy and safety of a 7-day low-dose rifabutin-based triple therapy with vonoprazan and amoxicillin. Our results suggest that our regimen was effective and safe as a third- or later-line H. pylori eradication regimen. To clarify what component in this regimen are critical, subsequent studies using a factorial design (comparing vonoprazan-amoxicillin dual therapy vs. vonoprazan-rifabutin triple therapy) will be needed.

  • Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions Comment

    van Tienderen Gilles S., Li Ling, Broutier Laura, Saito Yoshimasa, Inacio Patricia, Huch Meritxell, Selaru Florin M., van der Laan Luc J. W., Verstegen Monique M. A.

    CANCER CELL (Cancer Cell)  40 ( 3 ) 226 - 230 2022.03

    ISSN  1535-6108

    　View Summary

    Reliable establishment of tumor organoids is paramount to advance applications of organoid technology for personalized medicine. Here, we share our multi-center experience on initiation and tumorigenic confirmation of hepatobiliary cancer organoids. We discuss current concerns, propose potential solutions, and provide future perspectives for improvements in hepatobiliary cancer organoid establishment.

  • Challenges for better diagnosis and management of pancreatic and biliary tract cancers focusing on blood biomarkers: A systematic review

    Tominaga H., Matsuzaki J., Oikawa C., Toyoshima K., Manabe H., Ozawa E., Shimamura A., Yokoyama R., Serizawa Y., Ochiya T., Saito Y.

    Cancers 13 ( 16 )  2021.08

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.

  • Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids.

    Marsee A, Roos FJM, Verstegen MMA; HPB Organoid Consortium, Gehart H, de Koning E, Lemaigre F, Forbes SJ, Peng WC, Huch M, Takebe T, Vallier L, Clevers H, van der Laan LJW, Spee B.

    Cell Stem Cell (Cell Stem Cell)  28 ( 5 ) 816 - 832 2021.05

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  19345909

    　View Summary

    Hepatic, pancreatic, and biliary (HPB) organoids are powerful tools for studying development, disease, and regeneration. As organoid research expands, the need for clear definitions and nomenclature describing these systems also grows. To facilitate scientific communication and consistent interpretation, we revisit the concept of an organoid and introduce an intuitive classification system and nomenclature for describing these 3D structures through the consensus of experts in the field. To promote the standardization and validation of HPB organoids, we propose guidelines for establishing, characterizing, and benchmarking future systems. Finally, we address some of the major challenges to the clinical application of organoids.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Page Top ▲

Presentations 【 Display / hide 】

  • 腸管上皮オルガノイドを用いたシングルセル解析により見えてきたこと

    齋藤義正

    日本生理学会 第100回記念大会, 

    2023.03
    , 

    Oral presentation (invited, special)

  • 誘導性CRISPR/dCas9を用いたC19MCの肝内胆管癌オルガノイドの分化における役割の解明

    葉 子祥、松崎 潤太郎、及川 千尋、金井 弥栄、齋藤 義正

    第81回 日本癌学会学術総会, 

    2022.09
    -
    2022.10
    , 

    Oral presentation (general)

  • 膵がんドライバー遺伝子変異誘導による形質変化の追跡

    及川 千尋、松崎 潤太郎、落谷 孝広、齋藤 義正

    第81回 日本癌学会学術総会, 

    2022.09
    -
    2022.10
    , 

    Oral presentation (general)

  • 難治性がんオルガノイドを用いた個別化医療の開発

    齋藤義正

    第4回Cell Based Assay Workshop, 

    2022.03
    , 

    Oral presentation (invited, special)

  • 胆道がん患者由来オルガノイドの樹立と創薬研究への応用

    齋藤義正

    患者由来がんモデル研究会2021, 

    2021.12
    , 

    Oral presentation (invited, special)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 国際協力による難治性がんオルガノイドライブラリーの構築

    2024.09
    -
    2027.03

    国際共同研究加速基金（海外連携研究）, Principal investigator

  • デザイナーエクソソームとオルガノイドを用いた個別化がん免疫療法の開発

    2024.06
    -
    2026.03

    挑戦的研究（萌芽）, Principal investigator

  • 胆道がん腫瘍微小環境の再構築による次世代オルガノイドの開発

    2024.04
    -
    2027.03

    基盤研究(B), Principal investigator

  • 抗真菌薬を基盤とした胆道・膵臓がんに対する新規治療薬の創製

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • NAD+およびエピゲノムの制御による老化メカニズムの解明と新たな抗加齢介入の開発

    2019.06
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory) , Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、ｍｉＲ－３４ａの発現量を低下させる方法及びがん幹細胞増殖抑制剤

    Date applied： 特願2015-142164  2015.07 

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • Asian Pacific Digestive Week 2018, Emerging Leader Lectureship

    2018.11

    Type of Award： Award from international society, conference, symposium, etc.

  • 第18回日本抗加齢医学会総会　最優秀演題賞

    齋藤義正, 2018.05, 腸管上皮オルガノイドを用いたステムセルエイジングの検討

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本抗加齢医学会優秀演題賞　

    内田諒英、齋藤義正、中岡哉彰、村松俊英、木村真規、齋藤英胤.　, 2016.06, 第16回 日本抗加齢医学会総会　プログラム・抄録集: 174, 2016/6/10/12., オルガノイド培養法により樹立した腸管上上皮幹細胞における stem cell aging の検討.　

    　View Description

    プログラム・抄録集: 174, 2016/6/10/12.

  • 日本抗加齢医学会優秀演題賞　

    木村真規、井手晴香、白井栄里奈、内田諒英、齋藤義正、齋藤英胤.　, 2016.06, 第16回 日本抗加齢医学会総会, 高脂肪食摂取時の脂肪組織における老化マーカー遺伝子の発現変化とDNAメチル化阻害薬の効果.　

    Type of Award： Award from Japanese society, conference, symposium, etc.

    　View Description

    プログラム・抄録集: 170, 2016/6/10/12.

  • 慶應義塾大学薬学部学部長賞

    2015

    Type of Award： Keio commendation etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD: (PHARMACOTHERAPEUTICS)

    2024

  • SPECIAL LECTURES BY GUEST SPEAKERS

    2024

  • SPECIAL LECTURES BY GUEST SPEAKERS

    2024

  • SEMINAR:(PHARMACOTHERAPEUTICS)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

display all >>

Page Top ▲